EPICS is a drug discovery and development company that invents and develops small molecule drugs targeting RNA epigenetic mechanisms involved in cancer development
Mission & Vision
EPICS’s mission is to utilize its expertise in drug discovery and development to invent novel clinical agents targeting serious unmet medical needs in oncology.We develop products to meet high value-added endpoints.
We constantly balance risk and reward in determining if and when to partner our programs.
Company timeline
- Mar 2018 EPICS Therapeutics incorporated as ULB (University of Brussels) spin-off
- Apr 2018 €7.2M seed-fund round completed
- Dec 2018 EPICS acquired Ogeda former assets, adding Drug Discovery and Capabilities
- Jan 2019 €14M Series A fund round completed
-
Franz Obermayr, PhD. Chief Executive Officer
-
Jean Combalbert, PharmD. PhD. Director, advisor to the CEO
-
Graeme Fraser, PhD. Chief Scientific Officer
-
Steven Ramael, MD Medical Director
-
Vincent Lannoy, PhD. Intellectual Property & Legal Director
-
Laurent Meeus, PhD EuroscreenFast Services Unit Director
-
Fernand Timsonet Administrative & Accounting Director
-
Guillaume Dutheuil, PhD. Head of Chemistry
-
Catherine Sorlet Head of Molecular Pharmacology
-
François Fuks, PhD. Chief Scientific Advisor
-
Michel Allé representing Bio Cap Invest SA, Director, Chair
-
Franz Obermayr Chief Executive Officer
-
Jean Combalbert Director, advisor to the CEO
-
François Fuks Scientific Adviser, Director
-
Alain Parthoens representing AQ Invest SA, Director
-
Caroline Thielen representing Sparaxis SA, Director
Barbara Wroblewski
Marketing Communication Manager Europe
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.